Provided by Tiger Fintech (Singapore) Pte. Ltd.

Teva Pharmaceutical

16.36
+0.26001.61%
Volume:4.44M
Turnover:72.27M
Market Cap:18.75B
PE:-11.28
High:16.61
Open:16.22
Low:16.05
Close:16.10
Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (A) and Teva Pharmaceutical (TEVA)

TIPRANKS
·
18 Dec 2024

Teva price target raised to $28 from $25 at Barclays

TIPRANKS
·
18 Dec 2024

Teva Pharmaceutical (TEVA) Gets a Hold from J.P. Morgan

TIPRANKS
·
18 Dec 2024

Equity Markets Fall as Fed Meeting Gets Underway

MT Newswires Live
·
18 Dec 2024

TD says Spyre has ‘superior TL1A program’ after Teva data

TIPRANKS
·
18 Dec 2024

Teva and Sanofi (SNY) Jump amid Impressive Drug Results

TIPRANKS
·
18 Dec 2024

Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG

TIPRANKS
·
18 Dec 2024

Sector Update: Health Care Stocks Mixed Tuesday Afternoon

MT Newswires Live
·
18 Dec 2024

Teva price target raised to $25 from $23 at BofA

TIPRANKS
·
18 Dec 2024

Update: Teva, Sanofi Shares Jump as Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease

MT Newswires Live
·
18 Dec 2024

Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations

GuruFocus.com
·
18 Dec 2024

Teva rises 19.2%

TIPRANKS
·
17 Dec 2024

U.S.-Listing of Teva Pharmaceuticals up 15.6% After Co's Bowel Disease Drug With Sanofi Meets Main Goals in Mid-Stage Trial

THOMSON REUTERS
·
17 Dec 2024

Teva Shares Soar on Early Bowel Disease Drug Data -- Barrons.com

Dow Jones
·
17 Dec 2024

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

Benzinga
·
17 Dec 2024

Teva, Sanofi Say Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease

MT Newswires Live
·
17 Dec 2024